Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Maintenance in Extensive Stage Small Cell Lung Cancer
NCT02875457Phase 3Unknown
- Sponsor
- Army Medical University
- Start
- Sep 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of Rivoceranib in small cell lung cancer (SCLC), sponsored by Army Medical University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02875457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875457.